Effect of omega-3 fatty acids supplementation in polycystic ovary syndrome patients

Effect of omega-3 fatty acids supplementation on metabolic status, serum levels of high-sensitivity of C-reactive protein, adiponectin and visfatin in polycystic ovary syndrome patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011083664N3

Enrollment

Registered

2011-02-03

Start date

2010-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 2 capsules of omega-3 containing 360 mg EPA and 240 mg DHA for 2 months. Intervention 2: Control group: 2 capsules containing sunflower oil for 2 months.

Placebo

Intervention group: 2 capsules of omega-3 containing 360 mg EPA and 240 mg DHA for 2 months

Control group: 2 capsules containing sunflower oil for 2 months

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: woman with polycystic ovary syndrome, 20-35 years old and BMI of 25-40. Exclusion criteria: thyroid disorders, hyperprolactinemia, Cushing syndrome, liver, kidney and cardiovascular disease, diabetes, pregnancy and lactation, smoking, use of anti obesity drugs, lipid lowering agent , glucocorticoids, anti coagulation drugs, use a lowering weight diet, have a usual sports program, receiving omega-3 supplement during 2 month ago and receiving any nutritional supplements during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: baseline and at the end of intervention. Method of measurement: enzymatic method.	—

Secondary

Measure	Time frame
Fasting serum insulin level and insulin resistance. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method and HOMA-IR formula.;Lipid profile(TG,LDL,HDL,Total cholesterol). Timepoint: baseline and at the end of intervention. Method of measurement: Enzymatic method with special kits for assessing TG,HDL and total cholesterol and friedewald equation for assessing LDL cholesterol.;Hs-CRP. Timepoint: baseline and at the end of intervention. Method of measurement: immunotorbidometric method.;Adiponectin. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method.;Visfatin. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method.	—

Measure

Time frame

Fasting serum insulin level and insulin resistance. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method and HOMA-IR formula.;Lipid profile(TG,LDL,HDL,Total cholesterol). Timepoint: baseline and at the end of intervention. Method of measurement: Enzymatic method with special kits for assessing TG,HDL and total cholesterol and friedewald equation for assessing LDL cholesterol.;Hs-CRP. Timepoint: baseline and at the end of intervention. Method of measurement: immunotorbidometric method.;Adiponectin. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method.;Visfatin. Timepoint: baseline and at the end of intervention. Method of measurement: Elisa method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Mohammadi

Tabriz University of Medical Science

e.mohamadi52@yahoo.com+98 41 1335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026